At a glance
ClinicalIndex Comparison Record- ✓Age 18–80 years (liver recipient)
- ✓Valid Fibroscan 402/530 with ≥10 measurements and IQR/Median stiffness <30% (if >7.1 kPa)
- ✓Liver recipient must have undergone transplantation
- ✕Donation after circulatory death (DCD)
- ✕No liver biopsy obtained during organ procurement
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors
In Brief
An observational study evaluating Fibroscan 402/530 for Liver Transplant and 4 related conditions. Completed, enrolled 160 participants across 3 sites.
Detailed Summary
The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.
Study Details
Timeline
Interventions
Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.